Navigation Links
New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI
Date:11/18/2009

s, or if they are taking anticoagulants (e.g., warfarin) or taking NSAIDs (e.g., ibuprofen or naproxen) for a long time, they should talk to their doctor, as they may be at an increased risk of bleeding.

If patients plan to have surgery or a dental procedure, they should tell their doctors that they are taking Effient. Patients should not stop taking Effient without first talking to the doctor who prescribed it for them, as this may result in increased risk of a clot in their stent, a heart attack or death.

Patients should get medical attention right away if they develop any of the following unexpected symptoms: fever, weakness, yellowing of the skin or eyes, or if skin becomes very pale or dotted with purple spots. These symptoms may be signs of a rare but potentially life-threatening condition called TTP, which has been reported with other medicines in this class that are like Effient, sometimes after a short time (less than 2 weeks).

For more information about Effient including prescribing information, please visit www.Effient.com.

About Daiichi Sankyo

A global pharmaceutical innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. Areas of primary focus for Daiichi Sankyo research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. For more information on Daiichi Sankyo, Inc., please visit

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates
2. OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy
3. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
4. Symmetry Medical Updates Full Year 2009 Financial Guidance
5. Long-Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax(R)-Brain
6. CVS Caremark Announces Updates to Flu Vaccine Program
7. NCCN Updates NHL Guidelines Following FDA Approval of Pralatrexate
8. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
9. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
10. CuraGen Updates CR011-vcMMAE Data at ASCO
11. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 /PRNewswire-iReach/ -- The 2013 ... NJ has attracted the greatest number of "Emerging" ... President, Mark Alexay .  "No ... to attend this year.  The show,s still 4 months ... companies.  This is a big surprise and great ...
(Date:5/21/2013)... , May 21, 2013  Decision ... and advisory firms for pharmaceutical and healthcare ... emerging agent on key efficacy endpoints, including ... has the most influence over surveyed U.S. ... hormone-receptor (HR-) positive, HER2-negative breast cancer. The ...
(Date:5/21/2013)... , May 21, 2013  IsoRay, Inc. (AMEX: ... it has entered into an exclusive international distribution agreement ... product line in Greece . IsoRay ... brachytherapy and medical radioisotope applications for brain cancer, lung ... ("gyn") cancer. IASIS Medical is ideally ...
Breaking Medicine Technology:Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show 2Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3
... , , BERLIN ... NKTR ) presented favorable data today on lead oncology program, ... investigational compound in ovarian cancer. These data were presented at ... Oncology (ESMO) 2009 Joint Multidisciplinary Congress in Berlin, Germany. , ...
... , , , ... a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase ... partial response rate and 50 percent stabilization rate in patients with metastatic ... at the joint 15th Congress of the European CanCer Organisation and 34th ...
Cached Medicine Technology:NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 2NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 3NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 4NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 5Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4
(Date:5/21/2013)... 21, 2013 Heritage Woods of Dwight ... affordable assisted living community, is hosting a Quality Home Health ... 2 p.m. on Tuesday, May 28. , The community, which ... older adults of all incomes, including those on Medicaid, who ... program is open to the public. There is no ...
(Date:5/21/2013)... the George Washington (GW) University School of ... the launch of the Avance Center for ... between SPHHS, the Maryland Multicultural Youth Centers, ... This university-community partnership aims to address public ... through research, mutual capacity building and prevention ...
(Date:5/21/2013)... 2013 Patients of Dr. Michael Shenk and ... teeth due to gum disease and would like permanent tooth ... treatment with laser gum surgery. Gum disease must ... success rate out of all tooth replacement options. , ... new procedure cleared by the Food and Drug Administration (FDA) ...
(Date:5/21/2013)... LEAWOOD, Kan. Primary care practice transformation on ... health care reform efforts aimed at achieving better ... Amid emerging evidence that transformation toward the patient-centered ... today,s health care environment, the U.S. Department of ... and Quality funded 14 studies to learn more ...
(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...
Breaking Medicine News(10 mins):Health News:Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis 2Health News:GW launches center to address health disparities in the Latino immigrant community 2Health News:GW launches center to address health disparities in the Latino immigrant community 3Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3
... Mass., Jan. 3 Boston Scientific,Corporation (NYSE: ... upcoming JP,Morgan Health Care Conference, in San Francisco., ... a 25-minute,presentation on Wednesday, January 9th, beginning at ... Executive Vice President,and Chief Financial Officer will join ...
... new retrospective study on the effects of N-acetylcysteine ... caused by acetaminophen poisoning has found that the ... higher incidence of liver recovery, and better survival ... issue of Liver Transplantation, a journal by John ...
... no raised risk to heart , , THURSDAY, Jan. 3 ... but controversial treatment for prostate cancer reduces long-term death ... as some specialists had feared. , In patients ... testosterone-lowering drugs and radiation therapy appeared to lower the ...
... ... issued, PARAMUS, N.J., Jan. ... forcing the conversion of its Series A,Convertible Preferred Stock. At 5:00 p.m., ... of common stock. All of the issued and outstanding shares of Series,A ...
... Insulet Corporation,(Nasdaq: PODD ), the manufacturer and ... that Duane DeSisto, Chief Executive,Officer, will participate in ... scheduled to present an overview of the Company,at ... 2008 at The Westin St.,Francis Hotel in San ...
... is a former Officer of Aetna, Inc., ... HSKA ) today announced that Ms. Louise McCormick ... http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ), "We pride ourselves on ... Board consisting of high quality, independent Directors,is critical ...
Cached Medicine News:Health News:Boston Scientific to Participate in JP Morgan Health Care Conference 2Health News:Treatment with NAC is associated with better outcomes for children with liver failure 2Health News:Combo Therapy Cuts Prostate Cancer Death Rates 2Health News:Combo Therapy Cuts Prostate Cancer Death Rates 3Health News:Smart Balance Announces Conversion of Convertible Preferred Stock 2Health News:Louise McCormick Joins Heska's Board of Directors 2Health News:Louise McCormick Joins Heska's Board of Directors 3
... The CritSpin whisper quiet, compact system ... clinic anywhere fast, accurate and cost effective ... Digital Reader, the CritSpin System offers a ... spin, complete cell packing - Meets NCCLS ...
... light over one smooth pulse duration, rather ... damage skin) that other technologies use. Palomar's ... water supply through the StarLux handpiece, down ... to as low as 4 degrees C. ...
Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: